Login +0086-27-59253327 sales@sun-shinechem.com

Pacritinib(SB1518) Catalog No : 122941

Chemical Information

Product NamePacritinib(SB1518)
Iupac Chemical Name(16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[,6.18,12]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 
SynonymsSB1518;SB 1518;SB-1518;Pacritinib;ONX 0803, BAX 2201 
Molecular FormulaC28H32N4O3 
Molecular Weight472.579 

Technical Data

Appearancepale-yellow powder 
Purity98% by HPLC 
SolubilitySoluble in DMSO 
Storage-20 ºC for 3 years 
Shipping ConditionShipped under ambient temperature 
Quality control HNMR HPLC


Pacritinib (puh-CRIT-i-nib) is an oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Activating mutations of JAK2 are implicated in certain blood-related cancers, including myeloproliferative neoplasms (MPNs), leukemia and certain solid tumors. FLT3 is a gene commonly found mutated in patients with acute myeloid leukemia (AML). Pacritinib has demonstrated encouraging results in Phase 1 and 2 studies for patients with myelofibrosis and may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.


Chemical Structure

122941 - Pacritinib(SB1518) | CAS 937272-79-2


Login to get price

Quick Order


Contact Us